Dr. Jingjing Yu to present new NDA data at the upcoming 6th Asia Pacific ISSX Meeting

Dr. Jingjing Yu  will be presenting a poster entitled “ANALYSIS OF IN VITRO TO IN VIVO PREDICTIONS OF TRANSPORTER-MEDIATED INHIBITION DRUG INTERACTIONS FOR DRUGS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION BTEWEEN 2013 AND 2016” at the upcoming 6th Asia Pacific ISSX Meeting in Hangzhou, China, May 11 – 14, 2018.

The poster will be on display throughout the meeting and poster presentation sessions will be held on Saturday, May 12th and Sunday, May 13th. 


April Newsletter available

The April Newsletter is now available. You can see this and past newsletters in the DIDB Resource Center. Please note that you must be signed in to access.

Do not hesitate to contact us with comments or suggestions.

DIDB Editorial Team


New Manuscript in Drug Metabolism and Disposition

Our most recent publication entitled “Risk of Clinically Relevant Pharmacokinetic-based Drug-drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016” by Yu et al. is now available on Drug Metabolism and Disposition online FastForward site (https://dmd.aspetjournals.org). This is an extensive review of the NDA data we analyzed for the DIDB platform, with useful supplemental tables summarizing the main clinical findings.

Do not hesitate to contact us if you have any questions.

Sincerely,

DIDB Editorial Team


March Newsletter available

The March Newsletter is now available. You can see this and past newsletters in the DIDB Resource Center. Please note that you must be signed in to access.

Do not hesitate to contact us with comments or suggestions.

DIDB Editorial Team


February Newsletter available

The February Newsletter is now available. You can see this and past newsletters in the DIDB Resource Center. Please note that you must be signed in to access.

Do not hesitate to contact us with comments or suggestions.

DIDB Editorial Team


New “Overall Effect” for in vivo studies to include absorption-based DDIs

As a result of our continuous efforts to expand the DIDB platform coverage of pharmacokinetic-based drug interactions beyond metabolism and transport, the following new “Overall Effect” categories are now available for in vivo DDI studies:

  •                 In Vivo Other Mechanism >20% Effect
  •                 In Vivo Other Mechanism No Effect

With the following Study subtypes

  1. pH dependency (absorption)
  2. Binding/chelation (absorption)
  3. Gastrointestinal motility (absorption)
  4. Plasma protein binding displacement (distribution)
  5. Enzyme down-regulation/up-regulation reversal (metabolism)
  6. Complex/multifactorial mechanism

As we increase the number of citations pertaining to these mechanisms, you will start seeing these new studies in the queries (dropdown menus) and their results. As a first step, we entered all pH-dependent DDI evaluations (both negative and positive results) with proton pump inhibitors and we will continue adding absorption-based DDIs to the platform during the coming months.

Should you have questions, comments or concerns, please contact us at didbase@uw.edu.

DIDB Editorial Team


New User’s Tutorials

New User’s Tutorials are available in the Resource Center.


January Newsletter available

The January Newsletter is now available. You can see this and past newsletters in the DIDB Resource Center. Please note that you must be signed in to access.

Do not hesitate to contact us with comments or suggestions.

DIDB Editorial Team